Drug Trial Radar · NCT07926321
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 13, 2026
Primary completion
Jan 27, 2028
Study completion Apr 20, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for adults aged 40 and older who have idiopathic pulmonary fibrosis (IPF). Women can only participate if they cannot get pregnant. The purpose of this study is to find out whether a medicine called BI 3810477 can slow down the worsening of lung function in people with IPF. Participants are put into 2 groups randomly, which means by chance. One group receives BI 3810477 and the other group receives placebo. Placebo looks like BI 3810477 but does not contain any medicine. Participants receive BI 3810477 or placebo for 12 weeks. Participants may continue their regular treatment for IPF during the study. Participants are in the study for about 6 to 7 months. During this time, they visit the study site regularly, about 18 times. Some of the visits may be done at the participant's home instead of the study site. Doctors regularly test how well the lungs work by doing lung function tests. They also look at lung scans and measure markers in the blood that are linked to lung health. The results are compared between the 2 groups to see whether BI 3810477 works. The doctors also regularly check participants' health and note any unwanted effects.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
PlaceboOther
Placebo
BI 3810477Biological
BI 3810477
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in forced vital capacity (FVC) [mL] at Week 12Time frame: At baseline and at Week 12.
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona
Newport Native MD, Inc
Newport Beach, California
Stanford University School of Medicine
Palo Alto, California
Yale University School of Medicine
New Haven, Connecticut
Avanza Medical Research Center
Pensacola, Florida
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic, Rochester
Rochester, Minnesota
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Clinical Research Associates of Central PA
DuBois, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Baylor University Medical Center
Dallas, Texas
University of Utah Health Sciences Center
Salt Lake City, Utah
Centre Hospitalier Universitaire de Liège
Liège, Belgium
Helsinki University Hospital
Helsinki, Finland
Tampere University Hospital
Tampere, Finland
Turku University Hospital / TYKS
Turku, Finland
Universitätsklinikum Aachen, AöR
Aachen, Germany
Vivantes Klinikum Neukölln
Berlin, Germany
Caritas-Krankenhaus St. Maria gGmbH
Donaustauf, Germany
Krankenhaus Bethanien gGmbH
Solingen, Germany
Helios Hanseklinikum Stralsund
Stralstund, Germany
University of Fukui Hospital
Fukui, Yoshida-gun, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, Fukuoka, Japan
Sapporo Medical University Hospital
Hokkaido, Sapporo, Japan
Kanagawa Cardiovascular and Respiratory Center
Kanagawa, Yokohama, Japan
Saiseikai Kumamoto Hospital
Kumamoto, Kumamoto, Japan
National Hospital Organization Kinki-Chuo Chest Medical Center
Osaka, Sakai, Japan
Hamamatsu University Hospital
Shizuoka, Hamamatsu, Japan
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas
Distrito Federal, Mexico
Centro de Investigacion Farmacologica del Bajío, S.C.
León, Mexico
Hospital Universitario Nuevo de Nuevo León - CEPREP
Monterrey, Nuevo León, Mexico
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitari de Bellvitge
L'Hospitalet Del LLobregat, Spain
Hospital Universitario De La Princesa
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Royal Devon and Exeter Hospital, Wonford
Exeter, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.